Latest Capital Equipment News

Imricor Medical Systems has achieved a major milestone with FDA clearance for its NorthStar Mapping System, the first MRI-native 3D cardiac mapping platform approved in the US. This approval positions Imricor at the forefront of MRI-guided cardiac procedures in the world’s largest electrophysiology market.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Australian Dairy Nutritionals Limited (AHF) is raising approximately $3.47 million through a pro-rata entitlement offer to accelerate its growth plans in China and enhance processing efficiency.

Amaero Ltd has lowered its FY2026 revenue guidance due to delayed U.S. government contracts but reports strong contracted revenue and a robust cash position heading into 2026.

Celsius Resources has postponed the final Feasibility Study for its Maalinao-Caigutan-Biyog Copper-Gold Project to January 2026, while engaging a top financial advisory firm to secure project financing amid strong international interest.

Theta Gold Mines has taken a significant step forward in its TGME Gold Project by securing key long-lead processing equipment from leading South African engineering firms, keeping its commissioning timeline on track for the end of 2026.

XRF Scientific has reported a robust September quarter with a 16% increase in revenue, driven by strong international sales and new product launches. The company is poised for further expansion with ongoing innovation and strategic focus on global markets.

Vault Minerals projects steady gold production in FY26 with growth through FY28, driven by key plant upgrades and the anticipated restart of Sugar Zone operations. The company plans significant capital and exploration investments while preparing to fully unwind its hedge book.

Trajan Holdings delivered solid FY2025 results with revenue up 7.4% to $166.5 million and improved profitability despite transient costs and a biotech syringe loss. The company refinanced debt and set an optimistic FY2026 guidance range.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, beating guidance and setting a solid foundation for FY26 with continued organic growth and improved profitability.

Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for FY25, marking a significant turnaround with a return to profit after tax attributable to owners of $2.2 million. The company also reduced net debt and improved EBITDA by 26.2%, driven by organic growth and strategic acquisitions.

Compumedics Limited reported a 2% revenue increase and a 22% jump in sales orders for FY25, driven by strong demand in sleep diagnostics and SaaS platforms, while navigating a net loss impacted by higher financing costs.